Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03680885 · ClinicalTrials.gov registry record · Early Phase 1

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

A Early Phase 1 study of ADHD and Controls, sponsored by PhenoSolve.

Completed
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT03680885 is a Early Phase 1 study of ADHD and Controls that has completed, run by PhenoSolve. The registered enrollment target is 20 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03680885, a Early Phase 1 study of ADHD and Controls, has completed, sponsored by PhenoSolve.

COMPLETED
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This work will assess the reliability of a simple painless test for the effectiveness of the commonly used local anesthetic lidocaine

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Lidocaine gel
  • DRUG Injected lidocaine

Study Locations (1)

New York

  • Jacobi Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2019-08-01
Est. Completion 2020-03-30
Phase Early Phase 1

Sponsor

PhenoSolve

3 total trials

What the Registry Record Tells You About NCT03680885

The ClinicalTrials.gov registry entry for NCT03680885 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (89% lower). The listed sponsor is PhenoSolve, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with ADHD appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03680885 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03680885 about?

NCT03680885 is a clinical study titled "Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness". This work will assess the reliability of a simple painless test for the effectiveness of the commonly used local anesthetic lidocaine

What is the current status of trial NCT03680885?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-01. Estimated completion is 2020-03-30.

What conditions does trial NCT03680885 study?

This clinical trial studies the following conditions: ADHD, Controls.

What interventions are being tested in trial NCT03680885?

The interventions under investigation include: Placebo (DRUG), Lidocaine gel (DRUG), Injected lidocaine (DRUG).

Who is sponsoring clinical trial NCT03680885?

This trial is sponsored by PhenoSolve, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03680885 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.